
— Street Talk Psychedelic biotech Psylo raises first funds

Anthony Macdonald, Yolanda Redrup and Kanika Sood

Oct 1, 2021 - 12.05pm

There's a growing pool of funds being invested in psychedelic research.

The latest biotech to get funded is Sydney-based pre-clinical company Psylo, which is aiming to develop a shorter acting version of psilocybin (the active molecule in magic mushrooms) and commercialise it as a treatment for severe mental illness.



Psilocybin is the psychedelic found in "magic mushrooms".

The company has a long road ahead, with the biotech still in the pre-clinical synthesising and screening phase where the company is creating and assessing molecules that could become therapy candidates, but it's banked \$1.1 million to fund its early research.

The round was led by Chris Hitchen's global micro-VC fund Possible Ventures, and had participation from a range of angel investors including <u>AirTree chairman and</u> <u>philanthropist Daniel Petre</u> and an unnamed strategic investor believed to be one of the big players in the psychedelic space.

The company's funding round follows Melbourne-based research group The Psychae Institute scoring \$40 million in funding earlier this year, while Creso Pharma moved into the space in March. The space is also attracting big investment dollars in the US, UK and Europe, with Beckley Psytech raising \$US80 million in August, Atai Life Sciences raising \$225 million for a NASDAQ listing in 2020 and new Chicago-based venture capital group Palo Santo raising \$35 million in July to support biotechs in this field.

Psylo, which was founded by Josh Ismin and counts Samuel Banister as its chief scientific officer, is in the current intake of Startmate companies.

"There's a lot of research yet to be done, it's still the very early days," Ismin said.

"The timeline for this sort of research is long, but in this space things are happening quicker and quicker, and we will see psychedelic treatments on the market [within 10 years]."

Lead investor Hitchen says a new generation of mental health medicine is needed.

"We're confident that new approaches will yield more effective alternatives, so we're proud to be backing the Psylo team on their breakthrough mission," he said.

Get a first look at tomorrow's headlines

Sign up to the Street Talk First Look newsletter

SIGN UP NOW

Anthony Macdonald co-edits Street Talk, specialising in private equity, investment banking, M&A and equity capital markets. He has 10 years' experience as a business journalist and worked at PwC, auditing and advising financial services companies. *Connect with Anthony on Twitter*. *Email Anthony at a.macdonald@afr.com*

Yolanda Redrup is an award-winning journalist who writes on technology and healthcare from our Melbourne newsroom. *Connect with Yolanda on* <u>Twitter</u>. *Email Yolanda at* <u>yolanda.redrup@afr.com.au</u>

Kanika Sood is a Street Talk reporter. Email Kanika at kanika.sood@afr.com.au

Save	Share		License article
READ MORE			
Street Talk	Capital raising	Funding	
Venture capita	Innovation	Biotech	

LATEST STREET TALK

Capital raising

Psychedelic biotech Psylo raises first funds

Startmate company Psylo is the latest company to attract funding for its pre-clinical psychedelic research.

12.05pm — Oct 1, 2021

Mergers & acquisitions

Semiconductor firm Archer Materials in \$15m placement

ASX-listed Archer Materials wants \$15 million to develop two quantum computing chips.

11.09am — Oct 1, 2021

Capital raising

King Island Sheelite raising \$31 million for Dolphin redevelopment

Tungsten explorer King Island Scheelite is raising \$31 million to fund the redevelopment of its Dolphin Tungsten Project.

10.42am — Oct 1, 2021

Mergers & acquisitions

ACCC checks out animal health giant Zoetis's takeover of Jurox

Hunter Valley's Jurox, which makes animal medications including a popular anaesthetic for dogs, received a takeover offer from NYSE-listed Zoetis. Now ACCC is considering areas of overlap in their product lines.

10.23am — Oct 1, 2021

Venture capital

Square Peg pays out \$650m to investors, as VC returns top \$1b

The new generation of venture capitalists are putting to bed any doubts surrounding their ability to realise returns for investors.

See all Street Talk

SPONSORED

The Daily Habit of Successful People

MY ACCOUNT

SUBSCRIBE

ABOUT US

CONTACT

MAGAZINES

COLUMNS

MARKETS DATA

LISTS

EVENTS

OUR NETWORK

TERMS AND CONDITIONS

© Copyright 2021 The Australian Financial Review

Site Map